Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey M Jacobson

Showing results (71-80 of 167) with videos related to

Pageof 17
Sort By:
Journal of Virology|March 30, 2018
Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNAZachary Strongin, Radwa Sharaf, D Jake VanBelzen, et al.
The Journal of Infectious Diseases|April 11, 2013
Improved treatment for primary HIV infection by interferon-alfa therapy? Does HCV treatment in HIV/HCV coinfected patients help us to test this hypothesis? Reply to zur Wiesch and van LunzenLivio Azzoni, Andrea S Foulkes, Emmanouil Papasavvas, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccineBrian Latimer, Roberta Toporovski, Jian Yan, et al.
Science Advances|December 19, 2025
Interleukin-2 is a potent latency reversal agent in people with treated HIV-1Michael L Freeman, Brian M Clagett, Konstantin Leskov, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 9, 2006
A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102Keith Henry, David Katzenstein, Deborah Weng Cherng, et al.
Plos One|May 20, 2016
HIV-1 Genetic Variation Resulting in the Development of New Quasispecies Continues to Be Encountered in the Peripheral Blood of Well-Suppressed PatientsWill Dampier, Michael R Nonnemacher, Joshua Mell, et al.
Virus Research|August 23, 2019
Investigating the distribution of HIV-1 Tat lengths present in the Drexel Medicine CARES cohortRobert W Link, Anthony R Mele, Gregory C Antell, et al.
The Journal of Infectious Diseases|September 13, 2014
Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286Allan R Tenorio, Ellen S Chan, Ronald J Bosch, et al.
Retrovirology|December 17, 2013
Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virionsArangassery Rosemary Bastian, Mark Contarino, Lauren D Bailey, et al.
The Journal of Infectious Diseases|June 27, 2013
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248Adriana Andrade, Susan L Rosenkranz, Anthony R Cillo, et al.
Pageof 17

Showing results (71-80 of 167) with videos related to

Sort By:
Pageof 17
Journal of Virology|March 30, 2018
Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNAZachary Strongin, Radwa Sharaf, D Jake VanBelzen, et al.
The Journal of Infectious Diseases|April 11, 2013
Improved treatment for primary HIV infection by interferon-alfa therapy? Does HCV treatment in HIV/HCV coinfected patients help us to test this hypothesis? Reply to zur Wiesch and van LunzenLivio Azzoni, Andrea S Foulkes, Emmanouil Papasavvas, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccineBrian Latimer, Roberta Toporovski, Jian Yan, et al.
Science Advances|December 19, 2025
Interleukin-2 is a potent latency reversal agent in people with treated HIV-1Michael L Freeman, Brian M Clagett, Konstantin Leskov, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 9, 2006
A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102Keith Henry, David Katzenstein, Deborah Weng Cherng, et al.
Plos One|May 20, 2016
HIV-1 Genetic Variation Resulting in the Development of New Quasispecies Continues to Be Encountered in the Peripheral Blood of Well-Suppressed PatientsWill Dampier, Michael R Nonnemacher, Joshua Mell, et al.
Virus Research|August 23, 2019
Investigating the distribution of HIV-1 Tat lengths present in the Drexel Medicine CARES cohortRobert W Link, Anthony R Mele, Gregory C Antell, et al.
The Journal of Infectious Diseases|September 13, 2014
Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286Allan R Tenorio, Ellen S Chan, Ronald J Bosch, et al.
Retrovirology|December 17, 2013
Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virionsArangassery Rosemary Bastian, Mark Contarino, Lauren D Bailey, et al.
The Journal of Infectious Diseases|June 27, 2013
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248Adriana Andrade, Susan L Rosenkranz, Anthony R Cillo, et al.
Pageof 17